These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3550644)

  • 1. [Antithrombotic properties of the active metabolite of molsidomine, SIN-1].
    Grodzinska L; Basista M; Koenig E
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):233-4. PubMed ID: 3550644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
    Basista M; Grodzińska L; Swies J
    Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of the formation of platelet thrombus by molsidomine and SIN-1 in the mesenteric vessels rats].
    Breddin HK; Weichert W
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):223-5. PubMed ID: 3550642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of sydnonimines derivatives on the antithrombogenic activity of endothelial cells in culture].
    Berenger FP; Cano JP; Rolland PH
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):241-3. PubMed ID: 3550646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease.
    Bieroń K; Grodzińska L; Kostka-Trabka E; Gryglewski RJ
    Wien Klin Wochenschr; 1993; 105(1):7-11. PubMed ID: 8438599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavernous application of SIN-I in rabbit and man: functional and toxicological results.
    Meyer MF; Taher A; Krah H; Staubesand J; Becker AJ; Kircher M; Mayer B; Jonas U; Forssmann WG; Stief CG
    Ann Urol (Paris); 1993; 27(3):179-82. PubMed ID: 8352581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
    Wildgrube HJ; Ostrowski J; Chamberlain J; Gärtner W; Stockhausen H
    Arzneimittelforschung; 1986 Jul; 36(7):1129-33. PubMed ID: 3768083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release of plasminogen activator by molsidomine and its active metabolite SIN-1.
    Klöcking HP; Hoffmann A; Markwardt F
    Pharmazie; 1987 May; 42(5):354. PubMed ID: 3671454
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparative study of the effects of molsidomine and 3-morpholinosydnonimine on the redox status of rat erythrocytes and reticulocytes.
    Marković SD; Vukajlović MDj; Ognjanović BI; Stajn AS; Zikić RV; Saicić ZS; Radojicić RM; Jones DR; Spasić MB
    Cell Biochem Funct; 2007; 25(3):251-8. PubMed ID: 16397909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine plasma concentrations.
    Stoschus B; Fernandez I; Heller J; Neubrand M; Sauerbruch T
    Hepatogastroenterology; 1999; 46(26):933-7. PubMed ID: 10370642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU; Förster W; Heinroth I
    Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diameter changes of epicardial coronary arteries and coronary stenoses after intracoronary application of SIN 1, a molsidomine metabolite].
    Schulz W; Wendt T; Scherer D; Kober G
    Z Kardiol; 1983 Jul; 72(7):404-9. PubMed ID: 6613236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the direct NO-donor SIN-1 on the interaction between platelets and stainless steel stents under dynamic conditions.
    Jung F; Mrowietz C; Seyfert UT; Grewe R; Franke RP
    Clin Hemorheol Microcirc; 2003; 28(4):189-99. PubMed ID: 12897410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-ischemic effects of SIN-1, a molsidomine metabolite, during coronary angioplasty and antiplatelet effects in humans].
    Darius H; Erbel E; Schmucker B; Reusch U; Meyer J
    Presse Med; 1988 May; 17(20):1033-6. PubMed ID: 2969099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative and adhesive responses of human neutrophils to nitrovasodilators in vitro: the role of protein kinases.
    Klink M; Tchorzewski H; Sulowska Z
    Mediators Inflamm; 2003 Dec; 12(6):345-53. PubMed ID: 14668094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Organ- and species-specific properties of glucose-6-phosphate dehydrogenase and the effect of molsidomine].
    Schraven V; Gruber C
    Arzneimittelforschung; 1988 Jan; 38(1):36-9. PubMed ID: 3365274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
    Żorniak M; Mitręga KA; Porc M; Krzemiński TF
    Can J Physiol Pharmacol; 2017 Feb; 95(2):111-121. PubMed ID: 27918857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic effect of captopril and enalapril in young rats.
    Buczko W; Kubik A; Kucharewicz I; Chabielska E
    Pol J Pharmacol; 2004; 56(1):97-104. PubMed ID: 15047983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of NO-donors on thrombus formation and microcirculation in cerebral vessels of the rat.
    Sasaki Y; Seki J; Giddings JC; Yamamoto J
    Thromb Haemost; 1996 Jul; 76(1):111-7. PubMed ID: 8819262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.